Michael A Eldon
6 Papers
43 Citations
Michael A Eldon is an academic researcher. The author has contributed to research in topics: Irinotecan & Cancer. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer
Chris E. Adkins,Chris E. Adkins,Mohammed I Nounou,Mohammed I Nounou,Tanvirul Hye,Afroz S. Mohammad,Afroz S. Mohammad,Tori B. Terrell-Hall,Tori B. Terrell-Hall,Neel K Mohan,Michael A Eldon,Ute Hoch,Paul R. Lockman,Paul R. Lockman +13 more
TL;DR: Elevated and prolonged tumor SN38 exposure after NKTR-102 administration appears responsible for increased survival in this model of breast cancer brain metastasis.
Phase I dose finding and pharmacokinetic study of NKTR-102 (PEGylated irinotecan): Early evidence of anti-tumor activity
M. J. Borad,John T. Hamm,Lee S. Rosen,Gayle S. Jameson,J. Utz,M. Mulay,Michael A Eldon,S. Dhar,L. Acosta,D. D. Von Hoff +9 more
TL;DR: A phase I trial of NKTR-102 to establish the maximum tolerated dose (MTD) and to characterize safety and pharmacokinetics in patients with refractory solid tumors found that sustained tumor inhibition is associated with increased SN38 exposure.
5
Dose-finding study of NKTR-102 in combination with cetuximab
John T. Hamm,D. Richards,R. K. Ramanathan,Carlos Becerra,Gayle S. Jameson,Jackie Walling,D. Gribben,S. Dhar,Michael A Eldon,D. D. Von Hoff +9 more
TL;DR: NKTR-102 shows evidence of clinical antitumor activity in combination with cetuximab and dose limiting toxicities observed in cycle 1 and safety data from subsequent cycles support further evaluation of this combination in appropriate tumor types.
4
Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors
TL;DR: The pharmacokinetics of EP and four metabolites including the active metabolite SN38 were described by an integrated popPK model, and Simulations evaluating the clinical importance of significant covariates indicated minimal change in areas under the curve and peak concentrations ofEP and SN38.
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.
Gayle S. Jameson,John T. Hamm,Glen J. Weiss,Carlos Alemany,Stephen P. Anthony,Michele Basche,Ramesh K. Ramanathan,Mitesh J. Borad,Raoul Tibes,Allen Lee Cohn,Ioana Hinshaw,Robert M. Jotte,Lee S. Rosen,Ute Hoch,Michael A Eldon,Robert A. Medve,Katrina Schroeder,Erica White,Daniel D. Von Hoff +18 more
TL;DR: Etirinotecan pegol showed substantial antitumor activity in patients with various solid tumors and a somewhat different safety profile compared with the irinotecans historical profile.